Societies

A groundbreaking moment from 2017— the FDA approval of Kymriah – St. Baldrick’s Foundation

Photo taken from St. Baldrick's Foundation/LinkedIn

May 31, 2024, 05:37

A groundbreaking moment from 2017— the FDA approval of Kymriah – St. Baldrick’s Foundation

St. Baldrick’s Foundation shared a post on LinkedIn:

“Today, we’re looking back on a groundbreaking moment from 2017— the FDA approval of Kymriah, the first gene therapy in the U.S. for kids with high-risk leukemia.

This life-saving treatment brought hope to kids like Austin. Diagnosed at 2 with acute lymphoblastic leukemia, Austin faced years of treatment, relapse, and a bone marrow transplant.

By 2013, his cancer had returned, leaving Kymriah as his last hope. Thanks to a St. Baldrick’s-supported clinical trial, Kymriah’s CAR T cells eradicated his cancer.

Now, Austin is 15, cancer-free, and thriving. He’s learning to drive, excelling in trap shooting, and dreaming of becoming a welder.

Kymriah represents hope for kids like Austin, and this hope begins with research — made possible by your support. Help support the next major childhood cancer breakthrough.”

Additional information.
Source: St. Baldrick’s Foundation/LinkedIn

Acute Lymphoblastic Leukemia Bone Marrow Transplant cancer CAR-T cells Childhood Cancer FDA gene therapy Kymriah Leukemia OncoDaily Oncology St. Baldrick's Foundation

Bernard Fox received SITC lifetime achievement award

Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Special Coverage